Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The system was built with patients in mind, and its compact design has the potential to expand access to the modality where it may have previously been lacking.
The San Francisco-based company says the updates will accelerate radiology workflows by removing administrative burdens and freeing up radiologists to spend more time reviewing imaging exams instead.
The method targets cancer stem cells, which are highly tumorigenic and known to play a significant role in relapse, cancer spread and treatment resistance.
Given the approach’s “superior prognostic value,” experts urged for the incorporation of tau PET into routine clinical evaluation in memory care clinics.
This year the Henry N. Wagner Jr., Image of the Year is actually a group of images displaying the efficacy of a 68Ga-DOTA-5G and 177Lu-DOTA-ABM-5G theranostic pairing that improves the detection and treatment of metastatic pancreatic cancer.
According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.
The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.